Phase 4 paladin study with iluvien® published in peer-reviewed journal ophthalmology

Atlanta, feb. 23, 2022 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (“alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that the 3-year results of the paladin study have been published in the peer-reviewed journal ophthalmology.
ALIM Ratings Summary
ALIM Quant Ranking